Research on the influence of CYP2A6 gene polymorphism on liver function injury in the treatment of hyperthyroidism with methimazole
10.3760/cma.j.cn115807-20250108-00017
- VernacularTitle:CYP2A6基因多态性对甲巯咪唑治疗甲状腺功能亢进症时出现肝功能损伤影响的研究
- Author:
Zuzhi ZHAO
1
;
Haixia ZHAO
;
Pengfei XU
;
Yinghao FAN
;
Peng SUN
;
Suqin ZHANG
;
Xinguang QIU
;
Jianhua LI
Author Information
1. 郑州大学第一附属医院甲状腺外科，郑州 450052
- Publication Type:Journal Article
- Keywords:
CYP2A6;
Hyperthyroidism;
Methimazole;
Gene polymorphism;
Liver injury
- From:
Chinese Journal of Endocrine Surgery
2025;19(4):527-532
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the influence of cytochrome P450 2A6 (CYP2A6) gene polymorphisms on liver function injury in patients with hyperthyroidism treated with methimazole.Methods:The study selected 90 patients with hyperthyroidism who were treated with methimazole in the Department of Thyroid Surgery at the First Affiliated Hospital of Zhengzhou University from Sept. 2023 to Aug. 2024 as the research subjects. Based on the occurrence of liver injury, they were divided into a liver injury group ( n=36) and a non-liver injury group (n=54). Peripheral blood DNA was extracted from the patients, and the CYP2A6 gene genotypes (rs8192725, rs8192720, and rs28399433) were detected using the polymerase chain reaction (PCR) amplification method. The association between CYP2A6 gene polymorphisms and liver injury induced by methimazole treatment in hyperthyroidism was analyzed. Results:The comparison of genotype distribution frequencies at the rs8192725 locus between the liver injury group and the non-liver injury group showed a statistically significant difference ( P<0.05). The AG and GG genotypes at the rs8192725 locus were protective factors against liver injury in patients with hyperthyroidism (AG vs. AA, OR: 0.21; 95% CI: 0.08-0.57; P<0.05; GG vs. AA, OR: 0.24; 95% CI: 0.06-0.89; P<0.05; AG+GG vs. AA, OR: 0.22; 95% CI: 0.09-0.54; P<0.05). The frequency of the G allele of rs8192725 in the liver injury group was significantly lower than that in the non-liver injury group (G vs. A, OR: 0.36; 95% CI: 0.19-0.70; P<0.05), indicating that it is a protective factor for liver injury in hyperthyroid patients receiving methimazole treatment. Conclusions:The CYP2A6 gene polymorphism at the rs8192725 locus is associated with the occurrence of liver injury in patients with hyperthyroidism treated with methimazole. The G allele may be a protective factor against liver injury in patients with hyperthyroidism, suggesting that individualized treatment plans can be developed based on the patient's genotype.
